For PGC-1α to serve as either a biomarker for diabetes susceptibility or a therapeutic target for glycemic control, precise identification of its tissue-specific actions is essential to mitigate the virus-induced adverse effects on glucose metabolism. This evidence concerns the gene PPARGC1A and diabetes mellitus.